ClinicalTrials.gov record
Completed Phase 3 Interventional

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

ClinicalTrials.gov ID: NCT00107939

Public ClinicalTrials.gov record NCT00107939. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 2:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Licarbazepine 750 ¿ 2000 mg/d as Adjunctive Therapy to an Atypical Antipsychotic in the Treatment of Manic Episodes of Bipolar I Disorder Over 6 Weeks

Study identification

NCT ID
NCT00107939
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
453 participants

Conditions and interventions

Interventions

  • Licarbazepine Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2004
Primary completion
Mar 31, 2007
Completion
Mar 31, 2007
Last update posted
Mar 21, 2017

2004 – 2007

United States locations

U.S. sites
22
U.S. states
14
U.S. cities
21
Facility City State ZIP Site status
Investigational Site Little Rock Arkansas 72201
Investigational Site Orange California 92868
Investigational Site Pico Rivera California 90660
Investigational Site San Diego California 92108
Investigational Site San Diego California 92126
Investigational Site Boca Raton Florida 33432
Investigational Site Atlanta Georgia 30308
Investigational Site Chicago Illinois 60640
Investigational Site Joliet Illinois 60435
Investigational Site Indianapolis Indiana 46222
Investigational Site Topeka Kansas 66606
Investigational Site Kansas City Missouri 64133
Investigational Site St Louis Missouri 63104
Invetigational Site Brooklyne New York 11201
Investigational Site Cedarhurst New York 11516
Investigational Site New York New York 10003
Investigational Site Cincinnati Ohio 45267
Investigational Site Columbus Ohio 43210
Investigational Site Providence Rhode Island 02903
Investigational Site Bellaire Texas 77401
Investigational Site Bellevue Washington 98004
Investigational Site West Allis Wisconsin 53227

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00107939, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 21, 2017 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00107939 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →